|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Outcomes of liver transplantation in patients with hepatorenal syndrome显示文摘Hepatorenal syndrome(HRS) plays an important role in patients with liver cirrhosis on the wait list for liver transplantation(LT). The 1 and 5-year probability of developing HRS in cirrhotic with ascites is 20% and 40%, respectively. In this article, we reviewed current concepts in HRS pathophysiology, guidelines for HRS diagnosis, effective treatment options presently available, and controversies surrounding liver alone vs simultaneous liver kidney transplant(SLKT) in transplant candidates. Many treatment options including albumin, vasoconstrictors, renal replacement therapy, and eventual LT have remained a mainstay in the treatment of HRS. Unfortunately, even after aggressive measures such as terlipressin use, the rate of recovery is less than 50% of patients. Moreover, current SLKT guidelines include:(1) estimation of glomerular filtration rate of 30 m L/min or less for 4-8 wk;(2) proteinuria > 2 g/d; or(3) biopsy proven interstitial fibrosis or glomerulosclerosis. Even with these updated criteria there is a lack of consistency regarding longterm benefits for SLKT vs LT alone. Finally, in regards to kidney dysfunction in the post-transplant setting, an estimation of glomerular filtration rate < 60 mL /min per 1.73 m2 may be associated with an increased risk of patients having long-term end stage renal disease. HRS is common in patients with cirrhosis and those on liver transplant waitlist. Prompt identification and therapy initiation in transplant candidates with HRS may improve post-transplantation outcomes. Future studies identifying optimal vasoconstrictor regimens, alternative therapies, and factors predictive of response to therapy are needed. The appropriate use of SLKT in patients with HRS remains controversial and requires further evidence by the transplant community. | Rohan M Modi Nishi Patel Sherif N Metwally Khalid Mumtaz | 2016 | World Journal of Hepatology2016，8，24： | 8 |
| 2 | Trends and outcomes of transarterial chemoembolization in hepatocellular carcinoma:a national survey显示文摘BACKGROUND:Transarterial chemoembolization(TACE) is a palliative procedure frequently used in patients with advanced hepatocellular carcinoma(HCC). We examined the national inpatient trends of TACE and related outcomes in the United States over the last decade.METHODS:We utilized the National Inpatient Sample(2002 to 2012) and performed trend analyses of TACE for HCC in all adult patients(age >18 years). Multivariate analyses for the outcomes of in-hospital 'procedure-related complications'(PRCs) and 'post-procedure complications'(PPCs) were performed. We also compared early(2002 to 2006) and late(2007 to 2012) eras by multivariate analyses to identify predictors of complications, healthcare resource utilization and mortality.RESULTS:Overall, 19058 patients underwent TACE for HCC where PRCs and PPCs were seen in 24.2% and 17.6% of patients, respectively. The overall trends in the use of TACE(P<0.001) and associated PRCs(P=0.006) were observed to be increasing. There was less mortality [adjusted Odds ratio(a OR):0.58; 95% CI:0.41, 0.82], reduced length of hospital stay(-1.87 days; 95% CI:-2.77,-0.97) and increased hospital charges($19232; 95% CI:11013, 27451) in the late era. Additionally, there was increased mortality(a OR:4.07; 95% CI:2.96, 5.59), PRCs(a OR:3.21; 95% CI:2.56, 4.02), and PPCs(a OR:2.70; 95% CI:2.11, 3.46) among patients with coagulopathy.CONCLUSIONS:There is an increasing trend of TACE utilization in HCC. However, the outcomes are worse in patients with coagulopathy. Although PRCs have increased, mortality has decreased in recent years. These findings should be considered during TACE evaluation in patients with HCC. | Khalid Mumtaz Nishi Patel Rohan M Modi Vihang Patel Alice Hinton James Hanje Sylvester M Black Somashaker Krishna | 2017 | Hepatobiliary & Pancreatic Diseases International2017，16，6： | 2 |
| 3 | Efficacy and safety of semaglutide in non-alcoholic fatty liver disease显示文摘BACKGROUND Non-alcoholic fatty liver disease(NAFLD)is the leading cause of chronic liver disease.The prevalence and disease burden of NAFLD are projected to exponentially increase resulting in significant healthcare expenditures and lower healthrelated quality of life.To date,there are no approved pharmacotherapies for NAFLD or non-alcoholic steatohepatitis(NASH).Semaglutide has glycemic and weight loss benefits that may be advantageous for patients with NAFLD.AIM To investigate the efficacy and safety of semaglutide in patients with NAFLD.METHODS MEDLINE,CENTRAL,and EMBASE were searched from inception to May 1,2023,to identify eligible randomized controlled trials(RCTs).Meta-analysis was performed using random effects model expressing continuous outcomes as mean differences(MD)or standardized MDs(SMD),and dichotomous outcomes as odds ratios(OR)with 95%confidence intervals(CI).Statistical heterogeneity was assessed using the Cochran’s Q test and I2 statistic.RESULTS Three RCTs involving 458 patients were included.Semaglutide increased the likelihood of NASH resolution(OR:3.18,95%CI:1.70,5.95;P<0.001),improvement in steatosis(OR:2.83,95%CI:1.19,6.71;P=0.03),lobular inflammation(OR:1.81,95%CI:1.11,2.96;P=0.02),and hepatocellular ballooning(OR:2.92,95%CI:1.83,4.65;P<0.001),but not fibrosis stage(OR:0.71,95%CI:0.15,3.41;P=0.67).Radiologically,semaglutide reduced liver stiffness(SMD:-0.48,95%CI:-0.86,-0.11;P=0.01)and steatosis(MD:-4.96%,95%CI:-9.92,0.01;P=0.05).It also reduced alanine aminotransferase(MD:-14.06 U/L,95%CI:-22.06,-6.07;P<0.001)and aspartate aminotransferase(MD:-11.44 U/L,95%CI:-17.23,-5.65;P<0.001).Semaglutide led to improved cardiometabolic outcomes,including decreased HgA1c(MD:-0.77%,95%CI:-1.18,-0.37;P<0.001)and weight loss(MD:-6.53 kg,95%CI:-11.21,-1.85;P=0.006),but increased the occurrence of GIrelated side effects(OR:3.72,95%CI:1.68,8.23;P=0.001).Overall risk of serious adverse events was similar compared to placebo(OR:1.40,95%CI:0.75,2.62;P<0.29).CONCLUSION Semaglutide is effective in the treatment of NAFLD while maintaining a well-tolerated safety profile.Future studies are required to evaluate its effects on fibrosis regression and different phases of NAFLD. | Kai Zhu Rohan Kakkar Daljeet Chahal Eric M Yoshida Trana Hussaini | 2023 | World Journal of Gastroenterology2023，29，37： | 2 |
| 4 | Requirment for vascular endothelial growth factor in wound and inflammation-related corneal neovascularization显示文摘 | Amano S Rohan R Kuroki M | 1998 | Invest Ophthalmol Vis Sci1998，39，5： | 1 |
| 5 | Requirmentfor vascular endothelial growth factor in wound and inflammation-related corneal neovascularization显示文摘 | Amano S Rohan R Kuroki M | 1998 | Invest Ophthalmol Vis Sci1998，39，5： | 1 |
| 6 | Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization显示文摘 | Amano S Rohan R Kuroki M | | 0，，01： | 1 |
| 7 | Chemically mediated rejection of dinoflagellate prey by the copepods Calanus pacificus and Paracalanus parvus:mechanisms, occurrence significance 显示文摘 | Huntley M E Sykes P Rohan S | 1986 | Mar Ecol Prog Ser1986，28，： | 1 |
| 8 | Continuous flow pho- tocatalytic reactor using ZnO-bentonite nanocomposite for degradation of phenol 显示文摘 | Satish M Rohan L Shailesh G | 2011 | Chemical Engineering Journal2011，172，23： | 1 |
| 9 | In situ analysis of the changes in expression of ovarian inhibin subunit mRNAs during follicle recruitment after ovulation in pigs显示文摘 | Garrett W M Mack S O Rohan R M | 2000 | Journal of Reproduction and Fertility2000，118，： | 1 |
| 10 | Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization显示文摘 | Amano S Rohan R Kuroki M Tolentino M Adamis AP | 1998 | Invest Ophthalmol Vis Sci1998，39，1： | 1 |
| 11 | Vascular smooth muscle cells derives from atherosclerotic human arteries exhibit greater adhesion,migration,and proliferation than venous cells显示文摘 | Faries P L Rohan D I Wyers M C | 2002 | J Surg Res2002，104，： | 1 |
| 12 | Vascular smooth muscle cells derived frorn atherosclerotic human arteries exhibit greater adhesion,rnigration,and proliferation than venous cells显示文摘 | FARIES P L ROHAN D I WYERS M C | 2002 | J Surg Res2002，104，： | 1 |
| 13 | Differential expression of VEGF isoforms in mouse during development and in the adult显示文摘 | Ng Y S Rohan R Sunday M E | 2001 | Dev Dyn2001，220，2： | 1 |
| 14 | Elevated expression of axin2and hnkd mRNA provides evidence that Wnt/beta-catenin signaling is activated in human colon tumor显示文摘 | Yah D Wiesmann M Rohan M | 2001 | Proc Natl Acad Sci USA2001，98，14： | 1 |
| 15 | Acetylaiton of anisole by acetic anhydride over a HBEA zeolites-origin of deactivation of the catalyst显示文摘 | ROHAN D CANAFF C CANAFF C GUISNET M | 1998 | J Catal1998，177，2： | 1 |
| 16 | Chemically-mediated rejection of dinoflagellate prey by the copepods Calanus pacificus and Paracalanus parvus: mechanism, occurrence and significance 显示文摘 | Huntley M Sykes P Rohan S | 1986 | Mar Ecol Prog Sot1986，28，： | 1 |
| 17 | Acttenuated expression of transcripts encoding granulosa cell-derived insulin-like growth factor binding protein 4 and 5 in the rat: a putative antiatretic effect显示文摘 | CHOI D ROHAN R M ROSENFELD R G | 1997 | Biol Reprod1997，56，： | 1 |
| 18 | Treatment algorithms in treat- ment - resistant depression 显示文摘 | Amsterdam JD Hornig - Rohan M | 1996 | Psychiatr Clin North Am1996，19，： | 1 |
| 19 | Using GammaDistribution to Determine Half-life of Rotenone, Applied inFreshwater 显示文摘 | ROHAN M FAIRWEATHER A GRAINGER N | 2015 | Science of the Total Environment2015，527，： | 1 |
| 20 | Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization显示文摘 | Amano S Rohan R Kuroki M Tolentino M Adamis AP | 1998 | Invest Ophthalmol Vis Sci1998，39，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员